Director Marcelo Bigal filed a Form 4 with the SEC on November 17, 2026, reporting the disposition of all directly held common stock, restricted stock units, and stock options in Pacira BioSciences, Inc. following the consummation of a cash merger with Viatris Inc.

Key Highlights

  • Merger completed November 17, 2026: Peach Purchaser Sub Inc., a Viatris subsidiary, merged with and into Pacira BioSciences, with Pacira continuing as a wholly owned subsidiary of Viatris.
  • Offer price of $36.50 per share: Each share of Pacira common stock was converted into the right to receive $36.50, net of applicable withholding taxes and without interest, according to the filing.
  • 11,393 shares disposed under transaction code U: Bigal disposed of 11,393 shares of common stock at $36.5 pursuant to the tender offer, leaving 6,405 shares.
  • 6,405 RSU-related shares canceled: The remaining 6,405 shares, attributable to RSU settlement, were canceled and converted into the right to receive the Offer Price in cash under transaction code D.
  • Four stock options canceled: Options covering 12,179, 11,279, 10,891, and 30,967 shares, with exercise prices of $28.68, $24.34, $23.42, and $29.80, respectively, were all disposed of on November 17, 2026, leaving zero options outstanding.
  • Beneficial ownership reduced to zero: Following all reported transactions, Bigal's direct beneficial ownership of Pacira common stock and all derivative securities stands at zero.

Bigal's Holdings Eliminated as Pacira BioSciences Merges into Viatris

According to the Form 4 filed on November 17, 2026, Marcelo Bigal, a director of Pacira BioSciences, Inc. (NASDAQ:PCRX), reported the complete elimination of his beneficial ownership in the company as a result of the merger described in an Agreement and Plan of Merger dated October 8, 2026, among Pacira BioSciences, Viatris Inc., and Peach Purchaser Sub Inc. The filing states that at the effective time of the merger on November 17, 2026, each outstanding share of Pacira common stock was converted into the right to receive $36.50 per share, net of applicable withholding taxes and without interest.

The filing reports two common stock transactions. First, 11,393 shares were disposed of under transaction code U at $36.5 per share pursuant to the cash tender offer, reducing Bigal's direct holdings to 6,405 shares. Second, those remaining 6,405 shares, described as attributable to outstanding restricted stock unit awards, were canceled under transaction code D at $36.5. The filing explains that each RSU outstanding immediately before the effective time, whether vested or unvested, was canceled and converted into the right to receive a cash amount equal to the number of shares issuable under the RSU multiplied by the $36.50 Offer Price, subject to applicable tax withholdings.

In Table II, the filing reports the disposal of four stock options, all on November 17, 2026, under transaction code D. These covered 30,967 shares at an exercise price of $29.80 (expiring 10/06/2033), 12,179 shares at $28.68 (expiring 06/12/2034), 11,279 shares at $24.34 (expiring 06/11/2035), and 10,891 shares at $23.42 (expiring 06/10/2036). The filing states that each option was canceled and converted into the right to receive a cash amount based on the excess of the Offer Price over the exercise price, and that any option with a per-share exercise price greater than or equal to the Offer Price was canceled with no consideration payable. All four reported options had exercise prices below $36.50. Following all reported transactions, Bigal's beneficial ownership of both common stock and derivative securities is listed as zero.

What Was Disclosed

Marcelo Bigal, a Pacira BioSciences director, reported the disposal of all common stock, RSUs, and stock options he held directly, following the November 17, 2026 effective date of the Viatris merger. All positions were reduced to zero beneficial ownership.